• DNA-PKcs Regulates CKD Progression via TAF7/mTORC1 Signaling

  2026-05-11

  This study elucidates how DNA-dependent protein kinase catalytic subunit (DNA-PKcs) promotes chronic kidney disease (CKD) progression in male mice by driving metabolic reprogramming through TAF7/mTORC1 signaling. By combining in vivo genetic models and in vitro assays, the authors identify DNA-PKcs inhibition as a promising approach to mitigate renal fibrosis and metabolic dysfunction in CKD.

• Precision Apoptosis Detection: Translating Mechanisms to Imp

  2026-05-10

  This thought-leadership article explores the intersection of mechanistic apoptosis biology, advanced detection technologies, and strategic imperatives for translational researchers. Focusing on the Annexin V-APC/7-AAD Apoptosis Kit from APExBIO, we highlight cutting-edge applications in oncology and immunology, with evidence from MLL-rearranged ALL research and practical guidance for designing robust, clinically relevant assays.

• Maraviroc (UK-427857): Applied Workflows for CCR5 Antagonism

  2026-05-09

  Maraviroc, a potent CCR5 antagonist, is redefining how researchers interrogate HIV-1 entry and inflammatory signaling in cellular and disease models. This article details optimized workflows, troubleshooting strategies, and transformative applications, including targeted delivery via extracellular vesicles in rheumatoid arthritis, setting a new standard for experimental rigor.

• Rotavirus-Induced Downregulation of Nrf2 and Host Redox Defe

  2026-05-08

  This study reveals that progressive rotavirus infection leads to a robust downregulation of the redox-sensitive transcription factor Nrf2 and its associated cytoprotective genes, despite an initial oxidative stress response. The findings provide mechanistic insights into how rotavirus reprograms host redox signaling to favor viral persistence, with implications for antiviral strategy development.

• Honokiol Triggers Paraptosis-Like Death in APL via mTOR & MA

  2026-05-08

  This study demonstrates that honokiol, a natural compound, induces paraptosis-like cell death in acute promyelocytic leukemia (APL) cells by activating mTOR and MAPK signaling pathways. The findings highlight a caspase-independent mechanism distinct from apoptosis, offering new therapeutic insights for overcoming resistance in APL.

• Y-27632 dihydrochloride in Cancer EV Research: Precision Inh

  2026-05-07

  Explore how Y-27632 dihydrochloride, a potent ROCK inhibitor, enables precise suppression of extracellular vesicle (EV) release in triple-negative breast cancer. Uncover methodological insights and advanced assay guidance that set this cornerstone article apart from existing resources.

• Y-27632 dihydrochloride: Optimizing ROCK Inhibition in Stem

  2026-05-07

  Y-27632 dihydrochloride is a benchmark ROCK inhibitor enabling robust stem cell survival, reproducible cytoskeletal modulation, and high-fidelity disease modeling. This article delivers actionable workflows, data-driven troubleshooting, and practical insights from cutting-edge research and real-world experiments.

• Clozapine N-oxide: Precision Chemogenetics for Neuronal Modu

  2026-05-06

  Clozapine N-oxide (CNO) empowers neuroscience research with precise, non-invasive modulation of engineered neuronal circuits. This guide details high-impact workflows, data-driven optimization, and troubleshooting strategies for maximizing CNO’s transformative potential in chemogenetic and GPCR signaling studies.

• CHIR-99021: Optimizing Pluripotency and Differentiation Work

  2026-05-06

  CHIR-99021 (CT99021) enables precise modulation of GSK-3 activity, driving advances in stem cell maintenance and organoid differentiation. This guide integrates cutting-edge protocols, troubleshooting strategies, and translational insights from recent limb organoid research, ensuring robust, reproducible results for developmental and regenerative biology.

• PD98059 MEK Inhibitor: Precision Workflows for Apoptosis & N

  2026-05-05

  PD98059, a selective and reversible MEK inhibitor, unlocks targeted control over the MAPK/ERK pathway for high-precision studies in apoptosis and neuroprotection. This article delivers actionable workflows, troubleshooting, and comparative guidance to maximize reproducibility and insight—anchored by APExBIO’s trusted quality.

• Applied Workflows with the DiscoveryProbe Metabolism-related

  2026-05-05

  Empower advanced metabolism research with the DiscoveryProbe Metabolism-related Compound Library: a rigorously validated toolkit of 493 compounds for streamlined inhibition, activation, and pathway analysis. See how robust protocol design, troubleshooting, and cross-study insights drive reproducible results in metabolic disease and cancer biology.

• Vemurafenib (PLX4032) in Melanoma: Workflow, Resistance, and

  2026-05-04

  Vemurafenib (PLX4032) is the benchmark tool for dissecting BRAF-driven melanoma proliferation and resistance pathways. This article details experimental workflows, multi-omics insights, and hands-on troubleshooting for researchers seeking reproducibility and deeper mechanistic understanding.

• CD44-Mediated Metabolic Rewiring in IDH-Mutant Leukemia

  2026-05-04

  This article examines how CD44-driven metabolic rewiring supports NADPH generation and sustains high-level 2-hydroxyglutarate production in IDH-mutant leukemia. The study highlights CD44 as a targetable metabolic dependency, opening new avenues for combination therapies in AML.

• Protein A/G Magnetic Beads: Optimizing Immunoprecipitation W

  2026-05-03

  Protein A/G Magnetic Beads empower researchers to unravel complex protein-protein interactions with high specificity and low background. This article translates cutting-edge vascular research into actionable protocols and troubleshooting, ensuring robust immunoprecipitation outcomes for both routine and advanced applications.

• Bazedoxifene Inhibits IL-6/GP130 Signaling for Cancer Therap

  2026-05-02

  The reviewed study details how bazedoxifene, an FDA-approved SERM, acts as a small-molecule inhibitor of the IL-6/GP130 signaling axis, a key driver in cancer progression. The findings offer mechanistic clarity on bazedoxifene’s anticancer effects and implications for drug repurposing in oncology.

16708 records 1/1114 page Next 12345 下5页 Last page